Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 25, 2025Systematic ReviewsOpen Access

Hepatitis B reactivation with TNF-α inhibitors: assessing antiviral prophylaxis efficacy — protocol for systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMarouf AlhalabiSSSilvana Sedra

Discussion

Loading...

Member takes

Overview

Systematic review assesses antiviral prophylaxis effectiveness in preventing hepatitis B reactivation in patients on TNF-α inhibitors, highlighting associated risks.

Key Points

  • Antiviral prophylaxis significantly reduces hepatitis B reactivation in patients receiving TNF-α inhibitors.
  • Efficacy assessed using risk ratios, showing notable variation in reactivation rates among different treatments.
  • Systematic review adheres to PRISMA guidelines, emphasizing rigorous search and selection processes.
  • Standardized criteria for reporting hepatitis B reactivation in immunosuppressive treatments are urgently needed.

Cite This Study

Alhalabi et al. (2025) studied this question.

synapsesocial.com/papers/68af5d75ad7bf08b1eae151fhttps://doi.org/10.1186/s13643-025-02923-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TNF‐α Inhibitors and HBV Reactivation Risk in HBsAg−/Anti‐HBc+ Patients: A Systematic Review and Meta‐Analysis2026
  2. 2Risk of hepatitis B virus reactivation associated with interleukin inhibitor therapies: protocol for a systematic review and meta-analysis2025
  3. 3Hepatitis B Reactivation and Antiviral Prophylaxis in Patients on Immunosuppressive Therapy2026
  4. 4Hepatitis B Prophylaxis Outcomes in Patients Receiving Immunosuppressive Therapy: A Retrospective Cohort Study2026
  5. 5Antiviral prophylaxis to prevent hepatitis B reactivation in patients receiving anti–CD20-based chemotherapy and with inactive HBV infection: Systematic review and meta-analysis of randomized controlled trials.2026